VTGN News and Press, VistaGen Therapeutics Inc. From 11/09/23

2023-11-09 17:07:10 ET More on VistaGen Therapeutics Vistagen Therapeutics, Inc. (VTGN) Q1 2024 Earnings Call Transcript Vistagen prices $100M underwritten offering Vistagen in pact to issue a potential license for hot flashes therapy in Japan Seeking Alpha&#...

Fasedienol (PH94B) PALISADE Phase 3 Program for acute treatment of social anxiety disorder (SAD) advancing to build on recent positive PALISADE-2 Phase 3 results Preparations to initiate potential fasedienol NDA-enabling Phase 3 studies in 2024 underway Itruvone (PH10) sta...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Vistagen Therapeutics Inc. (VTGN) is expected to report for Q1 2024

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that company management will present and host one-on-one meetings...

Vistagen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, will be presenting at two scientific conferences in ...

Positive top-line results from fasedienol (PH94B) Phase 3 PALISADE-2 trial in social anxiety disorder (SAD) to be presented by SAD expert, Dr. Michael Liebowitz, at CNS Summit 2023 Positive results from PH80 Phase 2A study in women diagnosed with vasomotor symptoms (hot flashes) due to me...

Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company has announced that it will host a conference call...

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Thursday, Novembe...

2023-10-17 08:26:49 ET SciSparc  ( SPRC ) +105% . AgriFORCE Growing Systems  ( AGRI ) +34% . Monte Rosa Therapeutics  ( GLUE ) +17% Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and...